INtrODUctION
Hereditary angioedema due to C1-inhibitor deficiency (HAE-C1-INH) is a rare, autosomaldominant, potentially life-threatening disorder with a clinical picture characterized by recurrent, nonpruritic, self-limiting edema formation in the subcutaneous and/or submucosal tissues [1] .
Mutation of the gene of the C1-INH protein may lead to two different types of the disease.
In type I HAE, low levels of C1-INH protein can be due to intracellular degradation or lack of secretion from the cells synthesizing the protein, as well as defective transcription. In type II HAE, a nonfunctional inhibitor protein is transcribed; the serum level of which is normal or even appears elevated. The two types of HAE are phenotypically indistinguishable in the manner of clinical presentation [2, 3] . New mutations can also occur, as observed in approximately 15-25% of cases [4, 5] . 
HErEDItArY ANGIOEDEMA tYPE I AND tYPE II

Pathomechanism
C1-INH is a serine protease inhibitor (serpin)
that inactivates several different proteases: C1r, C1s, and mannose-binding-lectin-associated serine proteases in the complement system; factor XII and kallikrein in the contact system; factor XI and thrombin in the coagulation system; and tissue plasminogen activator and plasmin in the fibrinolytic system. C1-INH deficiency may result in activation of these four closely interrelated cascade systems, potentially leading to the release of bradykinin, resulting in edema formation [6, 7] .
Clinical Symptoms
Time of onset, frequency, duration, and severity Subcutaneous edema is not accompanied by pruritus or urticaria [1] . Cutaneous manifestations usually regress spontaneously over several days. Edema involving the submucosa of the upper airways can cause airways obstruction and, therefore, may rapidly lead to suffocation [1, 8, 9] .
Edema localized to the gastrointestinal mucosa may mimic clinical manifestations of the "acute abdomen" (including colicky abdominal pain, vomiting, watery post-attack diarrhea), which often lead to unnecessary surgery during the abdominal edematous attack [10] .
In a proportion of patients, exploration reveals the etiological role of certain factors in the evolution of edematous episodes. The most common triggering factors include mechanical trauma, surgical procedures performed in the head and neck region, mental stress, hormonal effects (menstruation, pregnancy), drug effects (e.g., of estrogen-containing oral contraceptives, angiotensin converting enzyme inhibitors), and certain infections [11, 12] . (Table 1) [13] .
Although genetic testing is not necessary in most patients, it may aid in the diagnosis of cases where biochemical measurements are inconclusive. However, the mutation responsible for C1-INH deficiency is only identified in 90-92% of patients with HAE-C1-INH [5] .
Complex Management
The management of patients with HAE requires a complex therapeutic approach that consists of the therapy and prevention of manifest edematous attacks [13] [14] [15] .
Management of Edematous Attacks
All attacks, irrespective of their location, are eligible for treatment as soon as they are clearly recognized by the patient [14] . The medicinal products appropriate for the treatment of edematous attacks differ according to their mechanisms of action ( Fig. 1) Leiden, The Netherlands) [19] . A novel Epinephrine may be administered as add-on therapy in upper airways involvement [23] .
Prophylaxis
The initial step of prophylaxis should be the The most appropriate strategy is to administer C1-INH concentrate 1 hour before surgery, or as close to the procedure as is feasible, but less than 6 hours before the intervention. Alternatively, attenuated androgens used for long-term prophylaxis may be administered in higher doses before surgery and for 4-5 days thereafter, to prevent an acute episode [13, 31, 32] .
C1-INH Ci
The C1-INH protein derived from human plasma is highly purified and equivalent to the 
Acute Attacks
In this study, the median time to onset of unequivocal relief from an attack was 2.41 hours in subjects treated with C1-INH concentrate, but longer than 4 hours in those given placebo (P = 0.02) [16] . The authors summarized the objectives, design, and primary and secondary endpoints, as well as the key findings of these studies in Table 2 [16, 37, 39] . 
Tolerability and Safety
C1-INH
The Safety and Efficacy of C1-INH Ci in Various Patient Populations
Pediatric Patients
The management of acute episodes
Overall, this open-label, multicenter study evaluated subjects aged ≥ 1 year, with a diagnosis of HAE; this subset analysis presents data on patients aged < 18 years. Twenty-two pediatric subjects [aged 2-5 years old (n = 1), 6-11 years old (n = 9), and 12-17 years old (n = 12)] experienced 121 HAE attacks in total, with 89% (108 of 121) achieving relief within 4 hours of C1-INH Ci administration. A 2-year-old subject was given at least 1 year, the median attack rate was consistently low at 0.34 per month (range 0-4.0). none of which were severe [43] .
C1-INH
Pregnant Women
Unlike placebo-controlled trials, pregnancy was [37, 48] .
Europe
The European Union approved C1-INH Ci in 2011
for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with HAE. Additionally, it is indicated for the routine prevention of severe and recurrent HAE attacks in adults and adolescents. In addition, the EMA granted approval for selfadministration and the medicine is available on medical prescription only [36] . 
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